Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKesson
Dow
Boehringer Ingelheim
Colorcon

Last Updated: January 29, 2022

Volunteer for clinical trials for NICOTINE POLACRILEX at ClinicalTrialExchange

DrugPatentWatch Database Preview

NICOTINE POLACRILEX Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Nicotine Polacrilex, and what generic alternatives are available?

Nicotine Polacrilex is a drug marketed by Ivax Sub Teva Pharms, L Perrigo Co, P And L, Perrigo R And D, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, and Pld Acquisitions. and is included in forty-seven NDAs.

The generic ingredient in NICOTINE POLACRILEX is nicotine polacrilex. There are thirty drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nicotine Polacrilex

A generic version of NICOTINE POLACRILEX was approved as nicotine polacrilex by P AND L on March 15th, 1999.

  Try it Free

Drug patent expirations by year for NICOTINE POLACRILEX
Drug Prices for NICOTINE POLACRILEX

See drug prices for NICOTINE POLACRILEX

Drug Sales Revenue Trends for NICOTINE POLACRILEX

See drug sales revenues for NICOTINE POLACRILEX

Recent Clinical Trials for NICOTINE POLACRILEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GlaxoSmithKlinePhase 1
22nd Century Group, Inc.Phase 1
Vince & Associates Clinical Research, Inc.Phase 1

See all NICOTINE POLACRILEX clinical trials

Pharmacology for NICOTINE POLACRILEX
Paragraph IV (Patent) Challenges for NICOTINE POLACRILEX
Tradename Dosage Ingredient NDA Submissiondate
NICORETTE TROCHE/LOZENGE;ORAL nicotine polacrilex 022360 2015-12-02

US Patents and Regulatory Information for NICOTINE POLACRILEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
P And L NICOTINE POLACRILEX nicotine polacrilex TROCHE/LOZENGE;ORAL 209519-001 Jul 2, 2018 OTC No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Aurobindo Pharma Ltd NICOTINE POLACRILEX nicotine polacrilex TROCHE/LOZENGE;ORAL 213266-002 Aug 3, 2021 OTC No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
P And L NICOTINE POLACRILEX nicotine polacrilex TROCHE/LOZENGE;ORAL 209519-002 Jul 2, 2018 OTC No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Colorcon
Merck
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.